Retatrutide 40mg

Triple GIP/GLP-1/Glucagon Receptor Agonist for Extended Metabolic Research Programs

Retatrutide 40mg provides pharmaceutical-grade triple incretin agonist for researchers conducting comprehensive long-term studies, large-scale comparative trials, and intensive investigation of synergistic GIP/GLP-1/Glucagon signaling. This high-dose comprehensive supply supports extended research protocols, multi-cohort studies, and in-depth mechanistic exploration of triple incretin biology across metabolic, cardiovascular, and hepatic systems representing the most advanced metabolic intervention available.

Research Applications & Mechanisms

• Long-Term Triple Incretin Biology: Investigate sustained GIP/GLP-1/Glucagon receptor co-activation, chronic multi-pathway signaling integration, receptor desensitization resistance, long-term metabolic adaptation mechanisms, and unprecedented sustained metabolic transformation
• Maximal Weight Loss & Body Recomposition: Study sustained 24-28% body weight reduction, maximal adiposity elimination, preferential visceral fat targeting, lean mass preservation, metabolic rate maintenance, and weight loss sustainability rivaling bariatric surgery outcomes
• Glucagon-Mediated Metabolic Advantages: Examine hepatic fat oxidation maximization, lipolysis amplification, energy expenditure optimization, thermogenic capacity enhancement, brown adipose tissue activation, and metabolic benefits unique to glucagon receptor activation
• Diabetes Remission & Beta-Cell Restoration: Explore comprehensive beta-cell function recovery, insulin independence achievement, HbA1c normalization to non-diabetic range, glucose variability elimination, and sustained diabetes remission mechanisms
• Hepatic Metabolic Transformation: Assess glucagon-driven hepatic steatosis elimination, NASH resolution, liver fibrosis reversal, hepatic inflammation suppression, and liver function normalization superior to all dual-agonist approaches
• Cardiovascular Outcome Optimization: Investigate comprehensive MACE reduction (myocardial infarction, stroke, cardiovascular death), atherosclerotic plaque regression, heart failure prevention, endothelial function restoration, and multi-factorial cardiovascular risk elimination
• Multi-Organ Protective Mechanisms: Study coordinated metabolic improvements across pancreas, liver, adipose tissue, skeletal muscle, cardiovascular system, kidney, brain, and gastrointestinal tract in metabolic syndrome models
• Renal Protection & Diabetic Nephropathy: Examine kidney function preservation, eGFR stabilization, albuminuria reduction, diabetic kidney disease intervention, and microvascular complication prevention
• Energy Balance & Metabolic Flexibility: Explore nutrient partitioning optimization, substrate utilization flexibility, metabolic efficiency enhancement, and adaptive thermogenesis regulation

Technical Specifications

• Purity: ≥98% 
• Structure: Engineered peptide with balanced triple GIP/GLP-1/Glucagon receptor agonist activity and extended pharmacokinetics
• Molecular Weight: ~5,960 Da
• Form: Lyophilized white to off-white sterile powder
• Half-Life: ~6-7 days via fatty diacid albumin binding and DPP-4 resistance
• Receptor Pharmacology: Balanced triple agonist with equivalent high-affinity GIP, GLP-1, and glucagon receptor binding
• Solubility: Water-soluble; reconstitute in bacteriostatic water (pH 7.0-7.4 optimal)
• Storage: 2-8°C refrigerated; protect from light and freezing
• Stability: Stable for 24 months refrigerated; reconstituted solutions stable 28 days at 2-8°C
• Reconstitution: Add 4mL bacteriostatic water for 10mg/mL concentration
• Price per vial.
• Free shipping.
• All sales final.

Ideal Research Scenarios

The 40mg high-dose comprehensive supply is engineered for laboratories conducting multi-month metabolic studies, large-cohort comparative trials, dose-ranging optimization, intensive mechanistic investigations, or translational research programs requiring extended material availability and maximum experimental flexibility.

Why Retatrutide Represents Breakthrough Metabolic Science

Retatrutide's triple GIP/GLP-1/Glucagon agonism represents the most advanced metabolic intervention ever developed, combining three complementary hormone pathways into a single molecule. The addition of glucagon receptor activation to proven GIP/GLP-1 dual agonism adds hepatic fat oxidation, enhanced energy expenditure, and amplified lipolysis—producing weight loss approaching 28% in clinical trials. This unprecedented efficacy, rivaling bariatric surgery outcomes through pharmacological intervention alone, makes Retatrutide the definitive tool for researchers investigating the limits of metabolic transformation, multi-receptor pharmacology, and the future of obesity therapeutics.

For research use only. Not for human consumption, therapeutic application, or weight management.